← Back to Dashboard

Ximency

NS3/4A protease + NS5A + NS5B polymerase inhibitors

Constituent drugs (3)

Daclatasvir

Could not render structureView on PubChem
3D not available

Asunaprevir

Could not render structureView on PubChem
3D not available

Beclabuvir

Could not render structureView on PubChem
3D not available

Chemical Identifiers

ClinicalTrials.govPubMed

Clinical Development by Virus1

Hepatitis C virus
HCV
Target: Viral NS3/4A + NS5A + NS5B
Approved (other)
Preclinical
Phase 2positive
Phase 3positive
Approved
Japan
Approval ref (kegg.jp) Approval ref (pmda.go.jp) PMDA approved 2016/12/19fixed-dose combination of Daclatasvir, Asunaprevir, Beclabuvir.